Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Array Biopharma, now a wholly owned subsidiary of Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histopathologically or cytologically confirmed solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for which the Investigator feels no other active therapy is required for the duration of the study.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
Estimated life expectancy of greater than or equal to 3 months.
Patient must have a tumor that is accessible for biopsy and must consent to paired tumor biopsies and normal skin biopsies being taken pre- and post-dose of study drug.
Additional criteria exist.
You may not be if
Uncontrolled or symptomatic brain metastases.
Use of investigational drug or device within 30 days prior to first dose of study drug.
Major surgery within 30 days prior to study start.
Radiotherapy or chemotherapy within 21 days prior to study start (not including palliative radiotherapy at focal sites).
Pregnancy or lactation.
Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
Additional criteria exist.
Clareo Health | A Study of ARRY-142886 in Patients With Advanced Cancer
